23602-63-3

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
5-CHLORO-2-HYDROXY-3-METHYLBENZALDEHYDE is utilized as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique chemical structure allows it to be a key component in the development of new drugs and pesticides.
Used in Flavor and Fragrance Industry:
5-CHLORO-2-HYDROXY-3-METHYLBENZALDEHYDE is employed as a flavor and fragrance ingredient in the food and beverage industry. Its distinct aromatic properties contribute to the creation of various scents and tastes in consumer products.
Used in Antimicrobial Applications:
5-CHLORO-2-HYDROXY-3-METHYLBENZALDEHYDE has been studied for its potential antibacterial and antifungal properties. It can be used as an active ingredient in antimicrobial formulations for various applications, such as disinfectants and preservatives.
Used in Research and Development:
Due to its unique chemical structure and potential biological activities, 5-CHLORO-2-HYDROXY-3-METHYLBENZALDEHYDE is also used in research and development for exploring new applications and understanding its mechanisms of action.

InChI:InChI=1/C9H9ClO2/c1-5-3-8(12)7(4-11)6(2)9(5)10/h3-4,12H,1-2H3

Upstream product

• 67-66-3 chloroform 
• 1570-64-5 2-methyl-4-chlorophenol 
• 50-00-0 formaldehyd 
• 925-90-6 ethylmagnesium bromide 
• 100-97-0 hexamethylenetetramine 
• 95-48-7 ortho-cresol 
• 578-58-5 2-methylmethoxybenzene 
• 3260-85-3 2-methyl-4-chloroanisole 

Downstream Products

• 179728-65-5 5-Chloro-2-(2,2-diethoxy-ethoxy)-3-methyl-benzaldehyde 
• 726191-05-5 tert-butyl (2E)-3-(5-chloro-2-hydroxy-3-methylphenyl)prop-2-enoate 
• 1105704-31-1 OHC₆H₂ClCH₃CH₂N(CH₂C₅H₄N)2 
• 1210749-61-3 C₈H₆ClNO 
• 82129-11-1 5-chloro-2-methoxy-3-methylbenzaldehyde 
• 726191-06-6 tert-butyl 3-(5-chloro-2-hydroxy-3-methylphenyl)-3-(hydroxyamino)propanoate 

Relevant academic research and scientific papers

Synthesis of deuterated benzopyran derivatives as selective COX-2 inhibitors with improved pharmacokinetic properties

We designed a series of specifically deuterated benzopyran analogues as new COX-2 inhibitors with the aim of improving their pharmacokinetic properties. As expected, the deuterated compounds retained potency and selectivity for COX-2. The new molecules possess improved pharmacokinetic profiles in rats compared to their nondeuterated congeners. Most importantly, the new compounds showed pharmacodynamic efficacy in several murine models of inflammation and pain. The benzopyran derivatives were separated into their enantiomers, and the activity was found to reside with the S-isomers. To streamline the synthesis of the desired S-isomers, an organocatalytic asymmetric domino oxa-Michael/aldol condensation reaction was developed for their preparation.

The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates

In this manuscript, we report the discovery of the substituted 2-trifluoromethyl-2H-benzopyran-3-carboxylic acids as a novel series of potent and selective cyclooxygenase-2 (COX-2) inhibitors. We provide the structure-activity relationships, optimization of design, testing criteria, and human half-life data. The challenge of a surprisingly long half-life (t 1/2 = 360 h) of the first clinical candidate 1 and human t 1/2 had been difficult to predict based on allometric scaling for this class of highly ppb compounds. We used a microdose strategy which led to the discovery of clinical agents 18c-(S), 29b-(S), and 34b-(S) with human half-life of 57, 13, and 11 h.

R-Isomers of Arg-Gly-Asp (RGD) mimics as potent αvβ3 inhibitors

The integrin αvβ3, vitronectin receptor, is expressed in a number of cell types and has been shown to mediate adhesion of osteoclasts to bone matrix, vascular smooth muscle cell migration, and angiogenesis. We recently disclosed the

THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES

The present invention relates to a class of compounds represented by the Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibiting or antagonizing the αVβ3 and/or the αV β5 integrin without significantly inhibiting the αV β6 integrin

3-Benzo[b]furyl- and 3-benzo[b]thienylaminobutyric acids as GABA(B) ligands. Synthesis and structure-activity relationship studies

Baclofen (β-p-chlorophenyl GABA) is one of the selective agonists for the bicuculline-insensitive GABA(B) receptors. In the search for new compounds that bind to GABA(B) receptors it is very important to clarify the structural requirements. We report the syntheses of and binding studies on various 3- heteroaromatic (benzo[b]furan and benzo[b]thiophen)aminobutyric acids. The 4- amino-3-(7-methyl-benzo[b]furan-2-yl)butanoic acid 8g is a potent and specific ligand for GABA(B) receptors, with an IC50 value of 5.4 μM in the displacement of [3H]GABA.